Trial · NCT04717700
Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
NCT04717700, Phase 2, Active not recruiting, Ida Bruun Kristensen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients. Trials, record NCT04717700. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04717700
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients
- NCT number
- NCT04717700
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Ida Bruun Kristensen
- Conditions
- Multiple Myeloma
- Interventions
- Selinexor 20 MG Oral Tablet, Bortezomib Injection, Lenalidomide capsule, Dexamethasone Oral
- First posted
- 2021-01-22
- Last updated
- 2026-10-16
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Increased ORR in arm B (defined as ≥PR) at end of induction, defined according to IMWG response criteria | Estimated at 4-8 weeks after end of induction | ORR at end of induction, with response defined according to IMWG response criteria |
| Secondary | Increased VGPR rate at end of induction in arm B | Estimated at 4-8 weeks after end of induction | VGPR rate at end of induction |
| Secondary | Increased rate of MRD negativity at end of induction in arm B | Estimated at 4-8 weeks after end of induction | MRD negativity by NGS at end of induction |
| Secondary | Decreased time to response in arm B | Estimated monthly during the first 64 weeks | Time to at least PR from start of treatment |
| Secondary | Evaluate toxicity rates between arm A and B, including rates of secondary primary malignancies | Estimated at 4-8 weeks after end of induction | Comparison of toxicity rates according to NCI-CTCAE v4.03 |
| Secondary | Decreased time to at least VGPR | Estimated monthly during the first 64 weeks | Time to at least VGPR from start of treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04717700
GET https://conductscience.org/api/trials/v1/NCT04717700/registered